Feature | October 10, 2014 Global medtech industry needs to better differentiate products or face commoditization Survey shows that while revenues stayed up, physician influence on purchasing decisions is declining Feature | Radiology Business | July 18, 2019 | By Stefanie Manack and Judy Zakutny Finding A Common Data Language for Radiology Approximately 30 percent of a hospital or health system’s profit comes from imaging according, to… read more Feature | Information Technology | July 31, 2019 | By Greg Freiherr How Smart Devices Can Improve Efficiency Innovation is trending toward improved efficiency — but not at the expense of patient safety, according to… read more October 10, 2014 — Despite ongoing commercial challenges in 2013, the global medtech industry’s financial performance held steady at the relatively low levels of growth that have become common in recent years. But even as the industry grapples with these market and regulatory pressures, it faces a potential growing challenge: the threat of commoditization, according to new findings outlined in EY’s annual medical technology report, Pulse of the industry: differentiating differently, released today. To understand how commoditization is playing out now and in the future, EY surveyed US and European health care buyers for the report in four major medtech markets: the US, the UK, Germany and Spain. Results from this latest survey, which interviewed 162 respondents, indicate that many medtech products could be judged primarily on price unless they are better able to demonstrate their ability to improve outcomes and/or lower health care costs. Glen Giovannetti, EY’s global life sciences leader, says: “As purchasing decisions become increasingly centralized and influence shifts from physicians to hospital administrators and managers, the historical value drivers for purchasing a device — brand, quality, and design — will lessen, leaving price as a main consideration. To achieve meaningful differentiation for their offerings, firms will need to design and market their products in ways that demonstrably improve patient outcomes while also lowering costs.” This year’s report also discusses annual financial performance, financing, and deal making trends and their potential impact on medtech business models, including reducing the challenge of commoditization. A Changing Customer Base and Evolving PrioritiesRespondents of the latest survey highlight overwhelmingly that price remains the top factor in medical technology purchasing decisions, with 77 percent selecting it as a top concern today and in the near future. However, over the next three years, respondents expect simple cost-cutting measures to become relatively less important, and instead anticipate healthcare reform initiatives focused on value and outcomes to become more important. Among six pressure points provided to respondents, such value and outcomes measures saw the largest percentage increase, jumping 13 percent between today and three years from now. Meanwhile, practicing physicians are expected to become significantly less influential when it comes to purchasing decisions over the next three years, on par with other functions such as finance and procurement departments. When asked to select the three most important factors in medical device purchasing decisions today compared to three years from now, the percentage of respondents who selected “Physician preference for a specific device” dropped from 55 percent today to 27 percent in the future, while “User-friendly design” dropped from 32 percent to 22 percent. Conversely, measures that target value and outcomes will become significantly more important influencers of purchasing decisions. “Data demonstrating clinical outcomes” was selected as a top purchasing decision factor by 51 percent of respondents today and by 62 percent in three years’ time. Risk-sharing agreements jumped from 6 percent to 25 percent over the three-year period. Financial Performance: Holding Steady Video Player is loading.Cynthia McCollough discusses bridging diversity gaps in medical physicsPlay VideoPlayMuteCurrent Time 0:00/Duration 6:05Loaded: 2.67%Stream Type LIVESeek to live, currently playing liveLIVERemaining Time -6:05 Playback Rate1xChaptersChaptersDescriptionsdescriptions off, selectedCaptionscaptions settings, opens captions settings dialogcaptions off, selectedAudio Trackdefault, selectedFullscreenThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Close Modal DialogThis is a modal window. This modal can be closed by pressing the Escape key or activating the close button. Videos | Radiology Business | August 02, 2019 VIDEO: Key Topics for Radiology Administrators at AHRA 2019 Association for Medical Imaging Management (AHRA) President … read more News | Radiology Business | August 01, 2019 Philips Completes Acquisition of Carestream Health’s HCIS Business … read more Taking advantage of healthcare’s warming financial climate and a pronounced uptick in market capitalization, medtech companies in the twelve months ending June 2014 charted modest revenue growth while strengthening their cash positions and using mergers and acquisitions (M&A) to deepen their product and service portfolios. Key financial results highlighted in the report include: Revenue ticks up: Revenue for public medtech companies in the U.S. and Europe totaled $336.2 billion in 2013, a 4 percent increase from the prior year, yet still well below pre-crisis growth rates;IPOs soar: The industry experienced one of its strongest IPO windows in recent years during the 12-month period ending June 2014. A total of 31 companies went public in the U.S. and Europe during this time, raising a total of $1.5 billion, a 600 percent increase from the previous time period;Financing remains strong: Medtechs raised $27.3 billion between July 2013 and June 2014, with 71 percent of the annual financing coming from debt transactions. While this is a 14 percent decrease from the prior year, it nevertheless represented the second-highest capital raise since 2008. U.S.-based companies raised the lion’s share of the total financing, which equaled $22.2 billion. Venture investment held steady at $4.4 billion compared to $4.2 billion during the same period the prior year, thanks partly to increased investment from corporate VCs and strategic investors;Deal activity heats up: For the 12-month period ending June 2014, the total value of M&A for U.S. and European medtechs jumped 135 percent to $85.6 billion. Excluding “megadeals,” defined as transactions greater than $10 billion, M&A for this time period still increased 28 percent to $29.3 billion. Medtechs were most interested in acquisitions that increased their scope in a disease area or geography, especially emerging markets; andCash returned to shareholders: Medtech companies returned 57 percent of their net cash generated through their operations to shareholders, totaling $16.7 billion, a 7 percent increase over 2012.Patrick Flochel, EY’s European life sciences leader and global pharmaceutical sector leader, says: “While the medtech industry continues to demonstrate resilience, our findings offer further evidence that the traditional rules of competition are becoming less relevant, requiring companies to implement new strategies to achieve sustainable success. While each organization’s chosen strategy will differ, every company must find new ways to demonstrate that its products help providers achieve top-quality care metrics and build market share while also taking costs out of the system.” For more information: www.ey.com/GL/en/Industries/Life-Sciences FacebookTwitterLinkedInPrint分享 Related Content Key Topics for Radiology Administrators at AHRA 2019Video Player is loading.Play VideoPlayMuteCurrent Time 0:00/Duration 7:33Loaded: 2.15%Stream Type LIVESeek to live, currently playing liveLIVERemaining Time -7:33 Playback Rate1xChaptersChaptersDescriptionsdescriptions off, selectedCaptionscaptions settings, opens captions settings dialogcaptions off, selectedAudio Trackdefault, selectedFullscreenThis is a modal window.Beginning of dialog window. Escape will cancel and close the window.TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaqueFont Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall CapsReset restore all settings to the default valuesDoneClose Modal DialogEnd of dialog window.Close Modal DialogThis is a modal window. This modal can be closed by pressing the Escape key or activating the close button. News | Radiation Oncology | July 17, 2019 CMS Proposes New Alternative Payment Model for Radiation Oncology The Centers for Medicare and Medicaid Services (CMS) issued a proposal for an advanced alternative payment model (APM)… read more Image by rawpixel from Pixabay Feature | Radiology Business | July 23, 2019 | Greg Freiherr Liars in Radiology Beware! Can you tell when someone is lying? read more Demand for ultrasound scans at U.S. outpatient centers could grow by double digits over the next five years, according to a speaker at AHRA 2019. A variety of factors, however, could cause projections for this and other modalities to change. Graphic courtesy of Pixabay Videos | AAPM | July 23, 2019 VIDEO: Bridging Diversity in Medical Physics to Improve Patient Care Cynthia McColl… read more Feature | Radiology Business | July 22, 2019 | By Greg Freiherr Payment Models Seek Traction in Transition from Volume Efforts to reform healthcare are booming, b read more News | Radiology Imaging | July 22, 2019 AHRA and Canon Medical Systems Support the 12th Annual Putting Patients First Program For the past twelve years, Canon Medical Systems USA, Inc. has partnered with read more John Carrino, M.D., M.Ph., presents “Challenges and Opportunities for Radiology to Prove Value in Alternative Payment Models” at AHRA 2019. Photo by Greg Freiherr Feature | Radiology Imaging | July 29, 2019 | By Greg Freiherr Imaging Market in U.S. Could Rise In Coming Years The coming years may be good for the medical imaging community in the United States. But they will not be easy. read more Body language expert Traci Brown spoke at the AHRA 2019 meeting on how to identify when a person is not being honest by their body language. She said medical imaging department administrators can use this knowledge to help in hiring decisions and managing staff.